UBS Group
SBIO icon

UBS Group’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

UBS Group’s Portfolio SBIO Stock Details SBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.42M Buy
46,189
+11,995
+35% +$610K ﹤0.01% 4801
2025
Q4 		$1.75M Buy
34,194
+581
+2% +$26.9K ﹤0.01% 5085
2025
Q3 		$1.31M Sell
33,613
-19,836
-37% -$682K ﹤0.01% 5333
2025
Q2 		$1.61M Sell
53,449
-1,983
-4% -$56.7K ﹤0.01% 5027
2025
Q1 		$1.58M Sell
55,432
-14,080
-20% -$445K ﹤0.01% 4899
2024
Q4 		$2.3M Buy
69,512
+7,918
+13% +$299K ﹤0.01% 4591
2024
Q3 		$2.3M Sell
61,594
-6,619
-10% -$241K ﹤0.01% 3856
2024
Q2 		$2.29M Sell
68,213
-20,311
-23% -$680K ﹤0.01% 3624
2024
Q1 		$3.16M Buy
88,524
+10,725
+14% +$371K ﹤0.01% 3455
2023
Q4 		$2.56M Sell
77,799
-717
-0.9% -$19.3K ﹤0.01% 3550
2023
Q3 		$2.14M Sell
78,516
-4,464
-5% -$134K ﹤0.01% 3380
2023
Q2 		$2.62M Sell
82,980
-7,668
-8% -$238K ﹤0.01% 3264
2023
Q1 		$2.46M Sell
90,648
-338
-0.4% -$10.2K ﹤0.01% 3208
2022
Q4 		$2.76M Sell
90,986
-86,457
-49% -$2.6M ﹤0.01% 3057
2022
Q3 		$5.35M Sell
177,443
-4,963
-3% -$157K ﹤0.01% 2295
2022
Q2 		$5.05M Sell
182,406
-39,164
-18% -$1.12M ﹤0.01% 2370
2022
Q1 		$7.45M Buy
221,570
+30
+0% +$1.04K ﹤0.01% 2175
2021
Q4 		$9.36M Sell
221,540
-5,496
-2% -$245K ﹤0.01% 2197
2021
Q3 		$10.3M Buy
227,036
+34,268
+18% +$1.57M ﹤0.01% 1994
2021
Q2 		$9.43M Sell
192,768
-11,435
-6% -$548K ﹤0.01% 2088
2021
Q1 		$10.3M Buy
204,203
+5,759
+3% +$319K ﹤0.01% 1928
2020
Q4 		$10.2M Sell
198,444
-2,763
-1% -$131K ﹤0.01% 1829
2020
Q3 		$8.28M Sell
201,207
-2,991
-1% -$123K ﹤0.01% 1779
2020
Q2 		$8.54M Sell
204,198
-13,659
-6% -$539K ﹤0.01% 1630
2020
Q1 		$6.91M Sell
217,857
-18,833
-8% -$720K ﹤0.01% 1664
2019
Q4 		$10M Sell
236,690
-2,261
-0.9% -$83.9K ﹤0.01% 1950
2019
Q3 		$7.54M Sell
238,951
-24,902
-9% -$875K ﹤0.01% 2004
2019
Q2 		$9.53M Buy
263,853
+3,937
+2% +$136K ﹤0.01% 1802
2019
Q1 		$9.4M Sell
259,916
-123
-0% -$4.11K ﹤0.01% 1719
2018
Q4 		$7.32M Sell
260,039
-187,187
-42% -$6.21M ﹤0.01% 1840
2018
Q3 		$17.6M Buy
447,226
+76,161
+21% +$2.89M 0.01% 1299
2018
Q2 		$13.8M Buy
371,065
+151,354
+69% +$5.49M 0.01% 1451
2018
Q1 		$7.52M Buy
219,711
+41,006
+23% +$1.44M ﹤0.01% 1937
2017
Q4 		$5.86M Buy
178,705
+16,283
+10% +$509K ﹤0.01% 2197
2017
Q3 		$5.06M Buy
162,422
+7,180
+5% +$211K ﹤0.01% 2196
2017
Q2 		$4.33M Buy
155,242
+39,806
+34% +$1.03M ﹤0.01% 2281
2017
Q1 		$2.97M Buy
115,436
+57,984
+101% +$1.44M ﹤0.01% 2556
2016
Q4 		$1.32M Buy
57,452
+26,262
+84% +$629K ﹤0.01% 3316
2016
Q3 		$814K Buy
31,190
+22,447
+257% +$560K ﹤0.01% 3566
2016
Q2 		$198K Buy
8,743
+3,370
+63% +$80K ﹤0.01% 4540
2016
Q1 		$117K Buy
5,373
+1,553
+41% +$35.5K ﹤0.01% 4859
2015
Q4 		$121K Sell
3,820
-7,970
-68% -$244K ﹤0.01% 5065
2015
Q3 		$329K Buy
11,790
+7,926
+205% +$277K ﹤0.01% 4233
2015
Q2 		$137K Buy
3,864
+3,036
+367% +$99.2K ﹤0.01% 5170
2015
Q1 		$25K Buy
+828
New +$23.3K ﹤0.01% 6741

Other funds holding SBIO

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CIS
Connors Investor Services Wyomissing, Pennsylvania $1.08B AUM 31.31% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
MWM
Moran Wealth Management Naples, Florida $3.27B AUM 25.8% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

UBS Group's SBIO Position: Q1 2026 in Review

UBS Group increased its ALPS Medical Breakthroughs ETF (SBIO) stake by 35% in Q1 2026, buying an estimated $610K and bringing the position to 46,189 shares worth $2.42M. The position accounts for ﹤0.01% of the portfolio, ranked #4801.

UBS Group first reported a position in SBIO in Q1 2015 and has held it in 45 quarters since. The position peaked at $17.6M in Q3 2018. 59 funds tracked by Wall St. Rank hold SBIO as of Q1 2026.

  • UBS Group held 46,189 shares of ALPS Medical Breakthroughs ETF worth $2.42M as of Q1 2026.
  • UBS Group bought 11,995 ALPS Medical Breakthroughs ETF shares in Q1 2026, an estimated $610K.
  • ALPS Medical Breakthroughs ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4801 holding.
  • UBS Group first reported a position in ALPS Medical Breakthroughs ETF in Q1 2015 and has held it in 45 quarters since.
  • UBS Group's ALPS Medical Breakthroughs ETF position peaked at $17.6M in Q3 2018.
  • 59 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.